Previous close | 1.9700 |
Open | 2.0200 |
Bid | 1.9500 x 1000 |
Ask | 2.0300 x 1200 |
Day's range | 1.9200 - 2.0380 |
52-week range | 1.0750 - 15.5580 |
Volume | |
Avg. volume | 151,200 |
Market cap | 58.715M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | -4.0040 |
Earnings date | 28 Mar 2022 - 01 Apr 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 15.00 |
Potential Angion Biomedica Corp. ( NASDAQ:ANGN ) shareholders may wish to note that the President, Jay Venkatesan...
Aerie Pharmaceutials (AERI) doses the first patient in a phase III study on its investigational TRMP8 agonist drug for the treatment of dry eye disease.
While a mid-stage/late-stage study evaluating Athersys' (ATHX) stem cell treatment for ischemic stroke misses out on its primary endpoint, top-line data shows evidence of therapeutic impact.